Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
US-9403829-B2 · Aug 2, 2016 · US
Treatment of cancer with TOR kinase inhibitors
US9937170B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9937170-B2 |
| Application number | US-201615277285-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 27, 2016 |
| Priority date | Oct 19, 2011 |
| Publication date | Apr 10, 2018 |
| Grant date | Apr 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for achieving complete response, partial response or stable disease, as determined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in a patient having a solid tumor, comprising administering to said patient an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridine-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein: said solid tumor is rapamycin resistant non-small cell lung cancer or rapacymin resistant breast cancer. 2. The method of claim 1 , wherein the solid tumor is an advanced solid tumor. 3. The method of claim 1 , wherein the solid tumor is non-small cell lung cancer. 4. The method of claim 1 , wherein the solid tumor is breast cancer. 5. The method of claim 4 , wherein the breast cancer is ER+/Her2, ER+/Her2+, ER-/Her2+or triple negative (TN).
Assignees
Inventors
Classifications
- A61K31/4985Primary
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Antineoplastic agents · CPC title
Ortho-condensed systems · CPC title
condensed with other heterocyclic ring systems, e.g. biotin, sorbinil · CPC title
- A61K31/4166Primary
having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9937170B2 cover?
- Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
- Who is the assignee on this patent?
- Signal Pharm Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4985. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).